22 August 2022
RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, announced the acceptance of a poster presentation at the European Society for Medical Oncology (ESMO) 2022 Congress to be held in person on 9-13 September 2022 in Paris – France.
Poster Title: Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
Location: Poster Area, Hall 4
Poster No: 1200TiP
Presenter: Prof. Dr. Hakan S. Orer, Medical Pharmacology, Koc University Hospital; Dr. Gülşah Nomak, Medical Director, RS Research
The poster abstract is available online at the ESMO website.
RS Research was founded by Prof. Rana Sanyal and Sena Nomak to take the necessary steps for bringing innovative therapies to patients, carrying out the research to clinic based on the proprietary drug delivery platforms SagittaTM Bir and SagittaTM Dui, patents covering 58 countries. Thanks to this technology, RS Research can increase effectiveness of chemotherapy and reduce side effects. The nanomedicine taken into the cell thanks to the targeting module that recognizes the receptors on the tumor surface, releases the active substance here, showing its full effect only to the tumor. The nanomedicine is released only when it is in the tumor after the targeting moiety recognize the cell surface receptors. RS Research raised 2 million Euros seed funding in 2017, followed by 12 million USD Series-A investment round in 2021. The company developed 5 drug candidates designed based on SagittaTM platform technology addressing multiple indications in its pipeline. The Phase I clinical trial of the leading drug candidate which received the first ever approval by the MoH to move towards clinical trials in Turkey is ongoing in two clinical research sites since May 2021. Further details regarding the clinical trial are available at clinicaltrials.gov with the trial identifier NCT04261413. RS Research’s clean room with both synthesis and filling capability was granted GMP license by the MoH for clinical batch lyophilized oncology drugs in August 2021.
For detailed information: